Ikena Oncology advances IK-175 combination cohort to stage two in Phase 1b trial for urothelial carcinoma

ImageneBio, Inc.

IK-175 (AHR antagonist) Phase 1b trial (NCT04200963) combination with nivolumab expansion cohort advanced to stage two in April 2022.
Patients are advanced/metastatic urothelial carcinoma progressed after multiple prior therapies including checkpoint inhibitors.
Simon two-stage design requires predefined ORR threshold (RECIST 1.1) to be met in stage one before advancing to stage two.
Monotherapy expansion cohort had previously advanced to stage two in September 2021.
Initial clinical data from the trial expected to be submitted to an oncology conference in H2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.